Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

Nathan Roberts, John Lister, N. Nora Bennani, Salvia Jain, Tammy Battaglia, Emily C. Ayers, Craig A. Portell, Michael E. Williams, Prem Batchala, Ipsita Pal, Owen A. O'Connor, John Sanil Manavalan, Enrica Marchi

Blood (2022) 140 (Supplement 1): 9425–9426.

https://doi.org/10.1182/blood-2022-170181

Published: 2022

Journal Articles

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jennifer Kimberly Lue, Don A. Stevens, Michael E. Williams, Jason Westin, Reggie Ewesuedo, Alice McDonald, Sagar Agarwal, Patrick Henrick, Rachelle Perea, Jared Gollob

Blood (2022) 140 (Supplement 1): 12143–12144.

https://doi.org/10.1182/blood-2022-170151

Published: 2022

Journal Articles

Nanoliposomal C6-Ceramide Exhibits Synergistic Anti-Cancer Activity with a Small Molecule Agonist of PP2A in Chronic Lymphocytic Leukemia

Kallesh D. Jayappa, Luke R. Vass, Caroline Farrington, Anuradha Illendula, Susan Walker, Michael E. Williams, Craig A. Portell, Todd Fox, Goutham Narla, Mark Kester

Blood (2022) 140 (Supplement 1): 7816–7817.

https://doi.org/10.1182/blood-2022-168086

Published: 2022

Journal Articles

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Blood (2022) 140 (17): 1907–1916.

https://doi.org/10.1182/blood.2022015560

Published: 2022

Includes: Supplemental data

Journal Articles

Novel Hemorrhagic Dermatologic Toxicity Associated with Bruton's Tyrosine Kinase Inhibitor Therapy

Nicholas J Schmidt, Jr., Krista Isaac, Michael E. Williams, Richard Flowers, Alina Zufall, Krishna Patel

Blood (2021) 138 (Supplement 1): 4528.

https://doi.org/10.1182/blood-2021-146587

Published: 2021

Journal Articles

Antibody and T-Cell Responses to Covid-19 mRNA Vaccines in Patients with B-Cell Lymphomas and Chronic Lymphocytic Leukemia (CLL)

Emily C. Ayers, Jeffrey Wilson, Glenda Canderan, Behnam Keshavarz, Judith Woodfolk, Craig A. Portell, Michael E. Williams

Blood (2021) 138 (Supplement 1): 1335.

https://doi.org/10.1182/blood-2021-146165

Published: 2021

Journal Articles

Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

Brad S. Kahl, Fangxin Hong, Christopher Peterson, Lode J. Swinnen, Thomas M. Habermann, Stephen J Schuster, Matthias Weiss, Paul A S Fishkin, W. Christopher Ehmann, Timothy S. Fenske, Michael E. Williams

Blood (2021) 138 (Supplement 1): 815.

https://doi.org/10.1182/blood-2021-152976

Published: 2021

Journal Articles

Mantle cell lymphoma continues to surprise, and inform!

Michael E. Williams

Blood (2021) 137 (23): 3158–3160.

https://doi.org/10.1182/blood.2020010622

Published: 2021

Journal Articles

Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia

Kallesh D. Jayappa, PhD, Caroline Farrington, PhD, Vicki L. Gordon, BS, Shekhar Saha, PhD, Christopher Morris, BS, Krista M. Isaac, MD, Timothy P. Bender, PhD, Michael E. Williams, MD, Craig A. Portell, MD, Goutham Narla, MD PhD, Michael J. Weber, PhD

Blood (2020) 136 (Supplement 1): 15–17.

https://doi.org/10.1182/blood-2020-138954

Published: 2020

Journal Articles

Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Craig A. Portell, MD, Nolan A Wages, PhD, Brad S. Kahl, MD, Lihua E Budde, MD PhD, Robert W. Chen, MD, Jonathon B. Cohen, MDMS, Gina Petroni, PhD, Michael E. Williams, MD

Blood (2019) 134 (Supplement_1): 1535.

https://doi.org/10.1182/blood-2019-128788

Published: 2019

Journal Articles

A Multi-Drug Tolerant Phenotype Is Induced By Diverse Microenvironmental Agonists in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Kallesh D. Jayappa, DVM, PhD, Konrad J. Cios, BSc (2019), Vicki L. Gordon, BSc, Puja C. Arora, MD, Timothy P. Bender, PhD, Michael E. Williams, MD, Craig A. Portell, MD, Michael J. Weber, PhD

Blood (2018) 132 (Supplement 1): 4120.

https://doi.org/10.1182/blood-2018-99-119521

Published: 2018

Journal Articles

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Kallesh D. Jayappa, DVM, PhD, Craig A. Portell, MD, Vicki L. Gordon, BSc, Goutham Narla, MD PhD, Timothy P. Bender, PhD, Michael E. Williams, MD, Michael J. Weber, PhD

Blood (2018) 132 (Supplement 1): 2649.

https://doi.org/10.1182/blood-2018-99-116759

Published: 2018

Journal Articles

Single Institution Experience of Gastrointestinal Involvement of Diffuse Large B- Cell Lymphoma: Presentation, Outcomes and Patterns of Treatment Failure

Puja C. Arora, MD, Victor M. Orellana-Noia, MD, Abeer Alfaraj, MBBS, Wenzinger Christopher, MD, Sandra Monson, PhD, Gina Petroni, PhD, Craig A. Portell, MD, Michael E. Williams, MD

Blood (2018) 132 (Supplement 1): 2982.

https://doi.org/10.1182/blood-2018-99-117651

Published: 2018

Journal Articles

Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma

Craig A. Portell, MD, Robert W Chen, MD, Nolan Wages, PhD, Jonathon B. Cohen, MD, Michael J. Weber, PhD, Gina Petroni, PhD, Brad S. Kahl, MD, Michael E Williams, MD

Blood (2016) 128 (22): 2958.

https://doi.org/10.1182/blood.V128.22.2958.2958

Published: 2016

Journal Articles

Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Kallesh D. Jayappa, DVM, PhD, Craig A. Portell, MD, Vicki L Gordon, BS, Brian J Capaldo, PhD, Stefan Bekiranov, PhD, Julia D Wulfkuhle, Rosa I Gallagher, Emanuel F. Petricoin, PhD, Timothy P. Bender, PhD, Michael E. Williams, MD, Michael J. Weber, PhD

Blood (2016) 128 (22): 754.

https://doi.org/10.1182/blood.V128.22.754.754

Published: 2016

Journal Articles

Major Bleeding with Ibrutinib: More Than Expected

Paul R Kunk, MD, Joesph Mock, MD, Michael E. Devitt, MD, Surabhi Palkimas, Pharm D., Jeremy Sen, Pharm D., Craig A. Portell, MD, Michael E. Williams, MD

Blood (2016) 128 (22): 3229.

https://doi.org/10.1182/blood.V128.22.3229.3229

Published: 2016

Journal Articles

Postibrutinib outcomes in patients with mantle cell lymphoma

Blood (2016) 127 (12): 1559–1563.

https://doi.org/10.1182/blood-2015-10-673145

Published: 2016

Journal Articles

Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma

Blood (2015) 126 (23): 3961.

https://doi.org/10.1182/blood.V126.23.3961.3961

Published: 2015

Journal Articles

Ligands That Mimic the Tissue Microenvironment of Replicating Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Protect Ex Vivo Patient Cell Samples from the Cytotoxicity of Combined Treatment with Ibrutinib and Venetoclax (ABT-199)

Kallesh D. Jayappa, PhD, Craig A. Portell, MD, Vicki Gordon, B.S., Michael E. Williams, MD, Emanuel F. Petricoin, PhD, Timothy P. Bender, PhD, Michael J. Weber, PhD

Blood (2015) 126 (23): 448.

https://doi.org/10.1182/blood.V126.23.448.448

Published: 2015

Journal Articles

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

Noa Biran, MD, Susanna Jacobus, David Siegel, MD PhD, Natalie Scott Callander, MD, Rafael Fonseca, MD, David H. Vesole, MD, Michael E. Williams, MD, Rafat Abonour, MD, Michael S Katz, BS,MBA, S. Vincent Rajkumar, Philip R. Greipp, MD

Blood (2015) 126 (23): 3174.

https://doi.org/10.1182/blood.V126.23.3174.3174

Published: 2015

NARROW

Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Nanoliposomal C6-Ceramide Exhibits Synergistic Anti-Cancer Activity with a Small Molecule Agonist of PP2A in Chronic Lymphocytic Leukemia

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Novel Hemorrhagic Dermatologic Toxicity Associated with Bruton's Tyrosine Kinase Inhibitor Therapy

Antibody and T-Cell Responses to Covid-19 mRNA Vaccines in Patients with B-Cell Lymphomas and Chronic Lymphocytic Leukemia (CLL)

Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

Mantle cell lymphoma continues to surprise, and inform!

Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia

Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

A Multi-Drug Tolerant Phenotype Is Induced By Diverse Microenvironmental Agonists in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Single Institution Experience of Gastrointestinal Involvement of Diffuse Large B- Cell Lymphoma: Presentation, Outcomes and Patterns of Treatment Failure

Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma

Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Major Bleeding with Ibrutinib: More Than Expected

Postibrutinib outcomes in patients with mantle cell lymphoma

Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma

Ligands That Mimic the Tissue Microenvironment of Replicating Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Protect Ex Vivo Patient Cell Samples from the Cytotoxicity of Combined Treatment with Ibrutinib and Venetoclax (ABT-199)

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only